Literature DB >> 16702586

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Gregory L Armstrong1, Annemarie Wasley, Edgar P Simard, Geraldine M McQuillan, Wendi L Kuhnert, Miriam J Alter.   

Abstract

BACKGROUND: Defining the primary characteristics of persons infected with hepatitis C virus (HCV) enables physicians to more easily identify persons who are most likely to benefit from testing for the disease.
OBJECTIVE: To describe the HCV-infected population in the United States.
DESIGN: Nationally representative household survey.
SETTING: U.S. civilian, noninstitutionalized population. PARTICIPANTS: 15,079 participants in the National Health and Nutrition Examination Survey between 1999 and 2002. MEASUREMENTS: All participants provided medical histories, and those who were 20 to 59 years of age provided histories of drug use and sexual practices. Participants were tested for antibodies to HCV (anti-HCV) and HCV RNA, and their serum alanine aminotransferase (ALT) levels were measured.
RESULTS: The prevalence of anti-HCV in the United States was 1.6% (95% CI, 1.3% to 1.9%), equating to an estimated 4.1 million (CI, 3.4 million to 4.9 million) anti-HCV-positive persons nationwide; 1.3% or 3.2 million (CI, 2.7 million to 3.9 million) persons had chronic HCV infection. Peak prevalence of anti-HCV (4.3%) was observed among persons 40 to 49 years of age. A total of 48.4% of anti-HCV-positive persons between 20 and 59 years of age reported a history of injection drug use, the strongest risk factor for HCV infection. Of all persons reporting such a history, 83.3% had not used injection drugs for at least 1 year before the survey. Other significant risk factors included 20 or more lifetime sex partners and blood transfusion before 1992. Abnormal serum ALT levels were found in 58.7% of HCV RNA-positive persons. Three characteristics (abnormal serum ALT level, any history of injection drug use, and history of blood transfusion before 1992) identified 85.1% of HCV RNA-positive participants between 20 and 59 years of age. LIMITATIONS: Incarcerated and homeless persons were not included in the survey.
CONCLUSIONS: Many Americans are infected with HCV. Most were born between 1945 and 1964 and can be identified with current screening criteria. History of injection drug use is the strongest risk factor for infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702586     DOI: 10.7326/0003-4819-144-10-200605160-00004

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  789 in total

1.  The seroprevalence of hepatitis C virus (HCV) among 559,890 first-time volunteer blood donors in China reflects regional heterogeneity in HCV prevalence and changes in blood donor recruitment models.

Authors:  Yongshui Fu; Wenjie Xia; Yizhong Wang; Linwei Tian; Oliver G Pybus; Ling Lu; Kenrad Nelson
Journal:  Transfusion       Date:  2010-04-23       Impact factor: 3.157

2.  Survey of US Correctional Institutions for Routine HCV Testing.

Authors:  Curt G Beckwith; Ann E Kurth; Lauri Bazerman; Liza Solomon; Emily Patry; Josiah D Rich; Irene Kuo
Journal:  Am J Public Health       Date:  2015-01       Impact factor: 9.308

3.  Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study.

Authors:  Helen S Yee; Sue L Currie; Kathryn Tortorice; Myrna Cozen; Hui Shen; Summer Chapman; Fran Cunningham; Alexander Monto
Journal:  Dig Dis Sci       Date:  2011-06-02       Impact factor: 3.199

4.  Incidence of primary liver cancer in American Indians and Alaska Natives, US, 1999-2009.

Authors:  Stephanie C Melkonian; Melissa A Jim; Brigg Reilley; Jennifer Erdrich; Zahava Berkowitz; Charles L Wiggins; Donald Haverkamp; Mary C White
Journal:  Cancer Causes Control       Date:  2018-07-20       Impact factor: 2.506

5.  Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.

Authors:  Melissa R Stein; Irene J Soloway; Karen S Jefferson; Robert J Roose; Julia H Arnsten; Alain H Litwin
Journal:  J Subst Abuse Treat       Date:  2012-10-02

6.  Associations of place characteristics with HIV and HCV risk behaviors among racial/ethnic groups of people who inject drugs in the United States.

Authors:  Sabriya L Linton; Hannah L F Cooper; Mary E Kelley; Conny C Karnes; Zev Ross; Mary E Wolfe; Yen-Tyng Chen; Samuel R Friedman; Don Des Jarlais; Salaam Semaan; Barbara Tempalski; Catlainn Sionean; Elizabeth DiNenno; Cyprian Wejnert; Gabriela Paz-Bailey
Journal:  Ann Epidemiol       Date:  2016-08-08       Impact factor: 3.797

Review 7.  Hepatitis C virus: an overview for dental health care providers.

Authors:  R Monina Klevens; Anne C Moorman
Journal:  J Am Dent Assoc       Date:  2013-12       Impact factor: 3.634

8.  Hepatitis C seroprevalence among prison inmates since 2001: still high but declining.

Authors:  Aiden K Varan; Daniel W Mercer; Matthew S Stein; Anne C Spaulding
Journal:  Public Health Rep       Date:  2014 Mar-Apr       Impact factor: 2.792

9.  Risky alcohol use and serum aminotransferase levels in HIV-infected adults with and without hepatitis C.

Authors:  Judith I Tsui; Debbie M Cheng; Howard Libman; Carly Bridden; Richard Saitz; Jeffrey H Samet
Journal:  J Stud Alcohol Drugs       Date:  2013-03       Impact factor: 2.582

Review 10.  Hepatitis C virus in pregnancy.

Authors:  Mona R Prasad; Jonathan R Honegger
Journal:  Am J Perinatol       Date:  2013-02-06       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.